The reasons for this are the lack of fully comprehensive and standardised registers for research funding as well as the core funding of research institutions or associations, which is often not only intended for NTD research (example here: DZIF TTU Malaria & NTDs). In addition, it is difficult to define in the case of grants, e.g. from the BMZ, whether these funds are also provided directly to finance research or primarily for capacity and infrastructure funding, as these aspects are closely linked in NTD research in particular. 

In 2020, the funding volume had already fallen below the previous year's figures, but in 2021 there was an increase in the funding volume (strongly supported by a high funding amount for a project of two research institutions).

On the one hand, this is a welcome commitment to NTD research in Germany and at EU level, as well as from a political perspective, but considering possible budget cuts and the already reduced funding volume in 2022, this harbours considerable risks for NTD research in Germany in the event of a further decline in this research funding.

Researchers are also active in WHO advisory committees and establish collaborations as part of product development partnerships with, for example, FIND or DNDi. Vaccine development for NTDs is in many cases cited as a low priority by the researchers. These classifications by the researchers are disease-specific in each case and show the broad requirements profile of NTDs with varying research priorities. Translational realisation by the research institutions can be found in the form of clinical studies and patent applications. 

Cooperation should extend across sectors and promote collaboration not only in the various disciplines of science, but also include sectors such as politics, non-governmental organisations and industry.